ANDI Andiamo Corporation (CE)

Anadis (ASX:ANX) (OTC:ANDIY), an Australian Biopharmaceutical company announced today its collaboration with Garden State Nutritionals, a New Jersey based division (GSN) of VitaQuest International in the field of dietary supplements. Anadis and GSN plans to introduce in the coming months and years a range of products, all based on Anadis� proprietary and all-natural milk-derived (colostrum) bioactives and immunoglobulins. The collaboration will allow Anadis to further expedite its penetration into the U.S. Vitamins and dietary supplements, a market which exceeds $15Bn in size, and which experiences growth rate in excess of 5% (Market research/Euro Monitor, 2007). GSN is one of the largest custom contract manufacturers of nutritional supplements in the United States, and is a leading producer of more than $1 billion in finished retail products per year. With advanced 250,000 sq. ft. manufacturing and packaging facility they produce more than 500 million doses per month and reach all geographical areas of the United States as well as supply to all major regional and national nutritional commercial channels. �Our expert and dedicated management team has an impressive average of more than 25 years of broad industry experience. We are thrilled to have Anadis with its proprietary Colostrum derived bioactives working with us. We see great potential in introducing Anadis to our more than 300 clients,� said Jon Weisgal, VP of Marketing, VitaQuest. Dr. Zeil Rosenberg, Anadis� New York City-based CEO, said: �GSN develops and manufacture cost-effective, market-leading dietary supplements products in every distribution channel, including health and natural food stores, mass merchandisers, network marketing and direct selling, television shopping, drug chain and direct response TV and radio.� Dr. Oren Fuerst, Anadis� New York City-based VP Business Development said: �Collaboration with GSN allows Anadis to offer our marketing partners complete turnkey solutions, including product concepts, formulations, laboratory services, package and label design, regulatory compliance and assistance in marketing and merchandising. The combination of GSN�s skills with our decade of R&D in the field of dairy-derived colostrum bioactives will now allow Anadis to rapidly penetrate the U.S. vitamins and dietary supplements market. This is a four way win combination to Anadis, GSN, the dietary supplements brands under which these products will be marketed, and above all consumers, who will be offered a broad range of new products based on our proprietary, all-natural colostrum platform." About GSN: GSN is one of the largest custom contract manufacturers of nutritional supplements in the United States. GSN has a highly skilled Product Development group, as well as a Scientific Advisory Board to help avail clients of the latest developments and technical innovations. This multidisciplinary team includes leading research scientists, molecular biologists, physicians, pharmacists, clinical nutritionists, herbalists, food technologists, and sports physiologists. GSN�s facilities are FDA-inspected and operate under strict Good Manufacturing Practices (GMP), and have earned the coveted NNFA GMP "A" Rating. GSN�s kosher-approved facilities have been audited and approved by leading independent bodies. GSN supplies dietary supplements to more than 35 countries around the world. Its Regulatory Affairs group works with customers and regional health authorities to ensure compliance in documentation requirements for each country. About Anadis (www.anadis.com): Anadis Limited (ASX:ANX) (OTC:ANDIY) is a biopharmaceutical company producing antibodies and other bioactive proteins as health products. Its all-natural, orally administered and colostrum-derived platform is proven safe and effective, with regulatory classification as GRAS (Generally Regarded as Safe) and BSE-free certification, allowing for rapid progression from concept to market. The company�s core technology relies on advanced dairy industry processing methods including immunization of pregnant cows with proprietary antigen specific vaccines, which in turn elicit an immune response by the cow. First-milking colostrum contains more than 35% immunoglobulin and this targeted antibody, along with other immune system bioactive nutrients, is subsequently harvested, fractionated and freeze dried under the highest dairy industry standards. The company is addressing a variety of unmet human health needs with broad market demand, including: Oral and GI Mucositis; Inflammatory Bowel Disease (IBD); Irritable Bowel Syndrome (IBS); Travellers� Diarrhea; Influenza, Clostridium Difficile and Rotavirus. The company operates from Melbourne, Australia and New York City.